Form 13-F position report

ACHILLES THERAPEUTICS PLC

Reported by Syncona Portfolio Ltd

ACHL CUSIP 00449L102 Manager CIK 0001725042

Reported 11,086,909 shares, unchanged from the prior quarter.

Reported value 40.6%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 9.24% This manager · Q1 2024
Shares 11,086,909 Quarter-end amount reported
Reported value $13,858,636 Fair value at quarter end
Consecutive quarters held 10 Through Q1 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 55545000
2022-03-31 55545000
2022-06-30 27939000
2022-09-30 25057000
2022-12-31 9978218
2023-03-31 10615715
2023-06-30 10479346
2023-09-30 10087979
2023-12-31 9856262
2024-03-31 13858636
2024-06-30 9035831
2024-09-30 11308647
2024-12-31 12639076
2025-03-31 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

14 quarters
Quarterly reported position history for ACHILLES THERAPEUTICS PLC held by Syncona Portfolio Ltd.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2025 Reduced 0 -11,086,909 (-100.0%) 0 $0 2025-05-07
Q4 2024 Unchanged 11,086,909 0 (0.0%) 23.86% $12,639,076 2025-02-06
Q3 2024 Unchanged 11,086,909 0 (0.0%) 14.01% $11,308,647 2024-11-14
Q2 2024 Unchanged 11,086,909 0 (0.0%) 10.52% $9,035,831 2024-08-13
Q1 2024 Unchanged 11,086,909 0 (0.0%) 9.24% $13,858,636 2024-05-07
Q4 2023 Unchanged 11,086,909 0 (0.0%) 6.25% $9,856,262 2024-02-01
Q3 2023 Unchanged 11,086,909 0 (0.0%) 15.03% $10,087,979 2023-11-01
Q2 2023 Unchanged 11,086,909 0 (0.0%) 15.8% $10,479,346 2023-07-27
Q1 2023 Unchanged 11,086,909 0 (0.0%) 17.26% $10,615,715 2023-05-12
Q4 2022 Unchanged 11,086,909 0 (0.0%) 15.84% $9,978,218 2023-02-14
Q3 2022 Unchanged 11,086,909 0 (0.0%) 43.54% $25,057,000 2022-11-04
Q2 2022 Unchanged 11,086,909 0 (0.0%) 39.7% $27,939,000 2022-08-10
Q1 2022 Unchanged 11,086,909 0 (0.0%) 53.06% $55,545,000 2022-05-31
Q4 2021 New 11,086,909 +11,086,909 (0.0%) 53.06% $55,545,000 2022-02-11

Who else reported the position

34 managers reported ACHILLES THERAPEUTICS PLC for Q1 2024.

Managers reporting ACHILLES THERAPEUTICS PLC in Q1 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Syncona Portfolio Ltd This report Unchanged 11,086,909 0 9.24% $13,858,636 10 qtrs
FCPM III SERVICES B V Unchanged 2,390,050 0 0.42% $2,987,563 2 qtrs
Redmile Group LLC Unchanged 1,608,089 0 0.07% $2,010,111 13 qtrs
Vestal Point Capital LP Added 1,500,000 +1,391,917 0.16% $1,875,000 2 qtrs
Ikarian Capital LLC New 1,443,181 +1,443,181 0.2% $1,803,976 1 qtr
STEMPOINT CAPITAL LP New 1,385,750 +1,385,750 0.46% $1,732,188 1 qtr
BAKER BROS ADVISORS LP Reduced 1,208,775 -894,017 0.02% $1,510,969 13 qtrs
RENAISSANCE TECHNOLOGIES LLC Added 1,005,759 +506,764 < 0.01% $1,257,000 10 qtrs
Artal Group S A Reduced 755,375 -1,500,000 0.02% $944,219 13 qtrs
BOOTHBAY FUND MANAGEMENT LLC New 420,481 +420,481 0.01% $525,601 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
March 31, 2024
Filed
May 07, 2024
Filing type
13F-HR
Position type
SPONSORED ADS

Voting authority reported

Sole
0
Shared
11,086,909
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.